Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer

Gregor Tevz; Sean McGrath; Ryan Demeter; Vincent Magrini; Varinder Jeet; Anja Rockstroh; Stephen McPherson; John Lai; Nenad Bartonicek; Jiyuan An; Jyotsna Batra; Marcel E. Dinger; Melanie L. Lehman; Elizabeth D. Williams; Colleen C. Nelson

doi:10.1016/j.mce.2015.10.011

Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer

Gregor Tevz, Sean McGrath, Ryan Demeter, Vincent Magrini, Varinder Jeet, Anja Rockstroh, Stephen McPherson, John Lai, Nenad Bartonicek, Jiyuan An, Jyotsna Batra, Marcel E. Dinger, Melanie L. Lehman, Elizabeth D. Williams, Colleen C. Nelson^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

Simultaneous expression of highly homologous RLN1 and RLN2 genes in prostate impairs their accurate delineation. We used PacBio SMRT sequencing and RNA-Seq in LNCaP cells in order to dissect the expression of RLN1 and RLN2 variants. We identified a novel fusion transcript comprising the RLN1 and RLN2 genes and found evidence of its expression in the normal and prostate cancer tissues. The RLN1-RLN2 fusion putatively encodes RLN2 isoform with the deleted secretory signal peptide. The identification of the fusion transcript provided information to determine unique RLN1-RLN2 fusion and RLN1 regions. The RLN1-RLN2 fusion was co-expressed with RLN1 in LNCaP cells, but the two gene products were inversely regulated by androgens. We showed that RLN1 is underrepresented in common PCa cell lines in comparison to normal and PCa tissue. The current study brings a highly relevant update to the relaxin field, and will encourage further studies of RLN1 and RLN2 in PCa and broader.

Original language	English
Pages (from-to)	159-168
Number of pages	10
Journal	Molecular and Cellular Endocrinology
Volume	420
DOIs	https://doi.org/10.1016/j.mce.2015.10.011
Publication status	Published - 15 Jan 2016
Externally published	Yes

Keywords

Prostate cancer
RLN1
RLN2
Fusion
SMRT sequencing
RNA-Seq

Access to Document

10.1016/j.mce.2015.10.011

Cite this

Tevz, G., McGrath, S., Demeter, R., Magrini, V., Jeet, V., Rockstroh, A., McPherson, S., Lai, J., Bartonicek, N., An, J., Batra, J., Dinger, M. E., Lehman, M. L., Williams, E. D., & Nelson, C. C. (2016). Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer. Molecular and Cellular Endocrinology, 420, 159-168. https://doi.org/10.1016/j.mce.2015.10.011

@article{d38ddd88209b4f26b28b534ecae1fc54,

title = "Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer",

abstract = "Simultaneous expression of highly homologous RLN1 and RLN2 genes in prostate impairs their accurate delineation. We used PacBio SMRT sequencing and RNA-Seq in LNCaP cells in order to dissect the expression of RLN1 and RLN2 variants. We identified a novel fusion transcript comprising the RLN1 and RLN2 genes and found evidence of its expression in the normal and prostate cancer tissues. The RLN1-RLN2 fusion putatively encodes RLN2 isoform with the deleted secretory signal peptide. The identification of the fusion transcript provided information to determine unique RLN1-RLN2 fusion and RLN1 regions. The RLN1-RLN2 fusion was co-expressed with RLN1 in LNCaP cells, but the two gene products were inversely regulated by androgens. We showed that RLN1 is underrepresented in common PCa cell lines in comparison to normal and PCa tissue. The current study brings a highly relevant update to the relaxin field, and will encourage further studies of RLN1 and RLN2 in PCa and broader. ",

keywords = "Prostate cancer, RLN1, RLN2, Fusion, SMRT sequencing, RNA-Seq",

author = "Gregor Tevz and Sean McGrath and Ryan Demeter and Vincent Magrini and Varinder Jeet and Anja Rockstroh and Stephen McPherson and John Lai and Nenad Bartonicek and Jiyuan An and Jyotsna Batra and Dinger, {Marcel E.} and Lehman, {Melanie L.} and Williams, {Elizabeth D.} and Nelson, {Colleen C.}",

year = "2016",

month = jan,

day = "15",

doi = "10.1016/j.mce.2015.10.011",

language = "English",

volume = "420",

pages = "159--168",

journal = "Molecular and Cellular Endocrinology",

issn = "0303-7207",

publisher = "Elsevier",

}

Tevz, G, McGrath, S, Demeter, R, Magrini, V, Jeet, V, Rockstroh, A, McPherson, S, Lai, J, Bartonicek, N, An, J, Batra, J, Dinger, ME, Lehman, ML, Williams, ED & Nelson, CC 2016, 'Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer', Molecular and Cellular Endocrinology, vol. 420, pp. 159-168. https://doi.org/10.1016/j.mce.2015.10.011

TY - JOUR

T1 - Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer

AU - Tevz, Gregor

AU - McGrath, Sean

AU - Demeter, Ryan

AU - Magrini, Vincent

AU - Jeet, Varinder

AU - Rockstroh, Anja

AU - McPherson, Stephen

AU - Lai, John

AU - Bartonicek, Nenad

AU - An, Jiyuan

AU - Batra, Jyotsna

AU - Dinger, Marcel E.

AU - Lehman, Melanie L.

AU - Williams, Elizabeth D.

AU - Nelson, Colleen C.

PY - 2016/1/15

Y1 - 2016/1/15

N2 - Simultaneous expression of highly homologous RLN1 and RLN2 genes in prostate impairs their accurate delineation. We used PacBio SMRT sequencing and RNA-Seq in LNCaP cells in order to dissect the expression of RLN1 and RLN2 variants. We identified a novel fusion transcript comprising the RLN1 and RLN2 genes and found evidence of its expression in the normal and prostate cancer tissues. The RLN1-RLN2 fusion putatively encodes RLN2 isoform with the deleted secretory signal peptide. The identification of the fusion transcript provided information to determine unique RLN1-RLN2 fusion and RLN1 regions. The RLN1-RLN2 fusion was co-expressed with RLN1 in LNCaP cells, but the two gene products were inversely regulated by androgens. We showed that RLN1 is underrepresented in common PCa cell lines in comparison to normal and PCa tissue. The current study brings a highly relevant update to the relaxin field, and will encourage further studies of RLN1 and RLN2 in PCa and broader.

AB - Simultaneous expression of highly homologous RLN1 and RLN2 genes in prostate impairs their accurate delineation. We used PacBio SMRT sequencing and RNA-Seq in LNCaP cells in order to dissect the expression of RLN1 and RLN2 variants. We identified a novel fusion transcript comprising the RLN1 and RLN2 genes and found evidence of its expression in the normal and prostate cancer tissues. The RLN1-RLN2 fusion putatively encodes RLN2 isoform with the deleted secretory signal peptide. The identification of the fusion transcript provided information to determine unique RLN1-RLN2 fusion and RLN1 regions. The RLN1-RLN2 fusion was co-expressed with RLN1 in LNCaP cells, but the two gene products were inversely regulated by androgens. We showed that RLN1 is underrepresented in common PCa cell lines in comparison to normal and PCa tissue. The current study brings a highly relevant update to the relaxin field, and will encourage further studies of RLN1 and RLN2 in PCa and broader.

KW - Prostate cancer

KW - RLN1

KW - RLN2

KW - Fusion

KW - SMRT sequencing

KW - RNA-Seq

UR - http://www.scopus.com/inward/record.url?scp=84951325478&partnerID=8YFLogxK

U2 - 10.1016/j.mce.2015.10.011

DO - 10.1016/j.mce.2015.10.011

M3 - Article

C2 - 26499396

SN - 0303-7207

VL - 420

SP - 159

EP - 168

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

ER -

Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this